Maze Therapeutics, Inc.
NASDAQ:MAZE · NASDAQ Global Market
+$0.18 today
Vol 1.05M · Avg 0.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-36.9%
avg -280.6%
ROIC
-37.7%
avg -65.2%
ROA
-33.0%
avg -57.1%
Analysis
ROA is currently the strongest return metric at -33.0% versus its period average of -57.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jason V. Coloma | Chief Executive Officer & Director | $1.09M | — | 50 | $344,897.00 | 0.62% |
Harold S. Bernstein | President of Research & Development and Chief Medical Officer | $874,583.00 | — | 66 | $207,554.00 | 0.38% |
Courtney J. Phillips | General Counsel & Corporate Secretary | $354,780.00 | — | 51 | $32,000.00 | 0.06% |
Misbah Tahir | CFO & Principal Accounting Officer | $304,940.00 | — | 51 | $325,000.00 | 0.59% |
Andrew Good | VP & Corporate Controller | — | — | — | — | — |
Vipin Vijayakumar | Vice President of R&D Infrastructure and Operations | — | — | — | — | — |
Winston Tse | Senior Vice President of Drug Discovery | — | — | — | — | — |
Nazila Habibizad | Senior Vice President of Technical Operations & Supply Chain | — | — | 63 | — | — |
Maarten Hoek | Senior Vice President of Research | — | — | — | — | — |
Matt Krause | Senior Vice President of Human Resources | — | — | — | — | — |
Amy Bachrodt | Senior Vice President of Finance | — | — | — | $33,833.00 | 0.06% |
Susan Limb | Senior Vice President of Clinical Development | — | — | — | — | — |
Atul Dandekar | Chief Strategy & Business Officer | — | — | 54 | $36,643.00 | 0.07% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
51
$15.09M
Net Sentiment
$15.09M
Net selling
Most Active
Bernstein Harold
20 transactions
1–10 of 51
Analysis
Insiders reported 0 buys worth $0.00 and 51 sells worth $15.09M over the last 12 months. That adds up to net selling of $15.09M. Bernstein Harold was the most active insider with 20 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.29B
Trevi Therapeutics, Inc.
NASDAQ:TRVI
$2.39B
Pharvaris N.V.
NASDAQ:PHVS
$2.28B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.90B
Immunome, Inc.
NASDAQ:IMNM
$1.73B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.69B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.68B
Ardelyx, Inc.
NASDAQ:ARDX
$1.43B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.17B
Who manages MAZE?
Maze Therapeutics, Inc. (MAZE) lists 13 active executives. The top listed executive is Misbah Tahir, CFO & Principal Accounting Officer.
Are MAZE insiders buying or selling?
Recent insider activity shows net buying of $6.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.